World News
-
GSK-Spero Therapeutics’ Utebzi earns FDA approval to combat rising global antimicrobial resistance
More than 3 million cases of complicated UTIs are recorded annually in the United States, and treatment failure affects up to one-third of patients.
-
WHO issues first comprehensive clinical guidelines for flavovirus care amid ongoing Bundibugyo outbreak
The new framework sets out 16 evidence-based recommendations designed to strengthen patient care and improve survival rates during outbreaks.
-
Moscow Study proves AI cannot replace human emergency radiologists
The analysis showed that the best results were achieved when AI acted as a “second reader,” supporting physicians rather than replacing them.
-
Protillion Biosciences secures US$510M Merck deal for AI biologics discovery
The agreement brings together Protillion’s computational biology platform with Merck’s established drug development expertise to support the discovery of next-generation therapies.
-
Zai Lab accelerates global launch plans for Zoci with landmark European ODD
The EMA Committee for Orphan Medicinal Products supported the designation after recognising a strong unmet need in neuroendocrine carcinomas.
-
Akeso secures China approval for Psoriasis Biologic Gumokimab
The approval adds a new option in the growing IL-17 inhibitor class and strengthens the company’s dermatology portfolio.
-
Johnson & Johnson invests US$1B to expand vision care manufacturing in Florida
The investment forms part of the company’s broader plan to spend US$55 billion on expanding its domestic manufacturing footprint through 2029.
-
Adial Pharmaceuticals acquires Azora Therapeutics in US$64M IBD pipeline pivot
The deal combines acquisition with a concurrent private placement of up to US$64 million in gross proceeds before expenses, strengthening development funding.
-
Medtronic completes US$550M acquisition of Scientia Vascular to strengthen the neurovascular access portfolio
Scientia Vascular develops advanced access products designed to improve simplicity and precision during neurovascular interventions.
-
Eli Lilly signs US$1B Alzheimer’s deal with AlzeCure Pharma for ACD680
The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.